In a highly expected move that could reshape medical device regulation, the U.S. Food and Drug Administration (FDA) is preparing to propose regulations that would classify laboratory developed tests (LDTs) as devices subject to their oversight. JD Supra reports that this action generates renewed debates about the agency’s authority and jurisdiction.
The FDA’s move is a step towards making explicit that LDTs, which are in-vitro diagnostics that are designed, manufactured, and utilized within a single laboratory, fall within the regulatory ambit of the agency, revisiting a longstanding area of ambiguity that has long sparked industry debates.
Such an adjustment to the FDA’s jurisdiction is likely to have considerable implications for a wide range of stakeholders. Laboratories, device manufacturers, and associated industry entities will need to prepare for a potentially altered regulatory landscape.
Notably, while the FDA has always maintained its right to regulate LDTs, historically, it has generally exercised “enforcement discretion” by not actively overseeing these tests. The change could, therefore, mean increased FDA enforcement and potential shifts in LDT design, development, and validation processes.
Critical questions, such as how existing LDTs will be treated under the new regulation and how the FDA plans to prioritize oversight of various LDTs, remain unanswered. These uncertainties underline the need for stakeholders to closely monitor the ongoing process and consider strategic approaches for potential changes.
The impending proposed regulation represents an essential development in FDA regulatory practice. Law firms and corporations closely connected to medical device industries are advised to follow the unfolding situation closely and adjust their strategies accordingly.